Generali Asset Management SPA SGR Cuts Holdings in Qiagen N.V. $QGEN

Generali Asset Management SPA SGR trimmed its holdings in shares of Qiagen N.V. (NYSE:QGEN) by 49.5% in the second quarter, HoldingsChannel.com reports. The institutional investor owned 33,968 shares of the company’s stock after selling 33,290 shares during the period. Generali Asset Management SPA SGR’s holdings in Qiagen were worth $1,633,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently bought and sold shares of the company. SVB Wealth LLC purchased a new position in Qiagen in the 1st quarter valued at approximately $31,000. Farther Finance Advisors LLC increased its stake in Qiagen by 400.5% in the 2nd quarter. Farther Finance Advisors LLC now owns 1,061 shares of the company’s stock valued at $51,000 after purchasing an additional 849 shares in the last quarter. Hilltop National Bank purchased a new position in Qiagen in the 2nd quarter valued at approximately $66,000. ANTIPODES PARTNERS Ltd purchased a new position in Qiagen in the 1st quarter valued at approximately $94,000. Finally, GAMMA Investing LLC increased its stake in Qiagen by 93.9% in the 1st quarter. GAMMA Investing LLC now owns 2,943 shares of the company’s stock valued at $118,000 after purchasing an additional 1,425 shares in the last quarter. 70.00% of the stock is owned by hedge funds and other institutional investors.

Qiagen Price Performance

QGEN stock opened at $48.29 on Friday. Qiagen N.V. has a 52-week low of $37.63 and a 52-week high of $51.88. The stock’s fifty day simple moving average is $47.00 and its 200-day simple moving average is $45.77. The company has a quick ratio of 1.35, a current ratio of 1.61 and a debt-to-equity ratio of 0.25. The stock has a market capitalization of $10.73 billion, a price-to-earnings ratio of 28.53, a price-to-earnings-growth ratio of 2.53 and a beta of 0.66.

Qiagen (NYSE:QGEN) last posted its quarterly earnings data on Tuesday, August 5th. The company reported $0.60 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.60. Qiagen had a return on equity of 14.77% and a net margin of 18.30%.The business had revenue of $533.54 million for the quarter, compared to analysts’ expectations of $523.97 million. During the same quarter last year, the firm earned $0.55 earnings per share. The business’s revenue was up 7.7% on a year-over-year basis. Qiagen has set its Q3 2025 guidance at 0.580- EPS. FY 2025 guidance at 2.350-2.350 EPS. Equities research analysts expect that Qiagen N.V. will post 2.26 EPS for the current year.

Analyst Ratings Changes

QGEN has been the subject of several research analyst reports. Barclays set a $53.00 price objective on Qiagen and gave the company an “overweight” rating in a research note on Thursday, October 2nd. Bank of America raised their price target on Qiagen from $50.00 to $53.00 and gave the stock a “buy” rating in a research report on Thursday, June 26th. Wall Street Zen downgraded Qiagen from a “buy” rating to a “hold” rating in a research report on Saturday, October 11th. Weiss Ratings reissued a “hold (c+)” rating on shares of Qiagen in a research report on Wednesday, October 8th. Finally, Cowen reissued a “hold” rating on shares of Qiagen in a research report on Thursday, August 7th. Three research analysts have rated the stock with a Buy rating and seven have given a Hold rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $49.69.

About Qiagen

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.